Abivax SA
ABVX
View Detailed Chart
117.670USD
+6.960+6.29%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+6.29%
5 Days
+5.87%
1 Month
-1.20%
6 Months
+70.31%
Year to Date
-12.74%
1 Year
+1853.03%
View Detailed Chart
TradingKey Stock Score
No stock score available due to insufficient data.
Abivax SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Abivax SA Info
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Ticker SymbolABVX
CompanyAbivax SA
CEOde Garidel (Marc)
Websitehttps://www.abivax.com/
Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69819.010
-151.120 (-0.22%)
282.580
+22.390 (+8.61%)
2070.400
+18.670 (+0.91%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
